SecBot SecBot

TGTX

TG THERAPEUTICS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001001316 Biotech & Drug Discovery
$54.79 +0.62 (+1.14%)
Oct 26 4:00 PM ET · prev $54.17
Market cap
$8.1B
Mid cap
Consensus
Buy
86% Buy or better · 14 analysts
Median target
$75.00
+37% · range $21.00–86.00
Next earnings
Nov 9
in 13 days · EPS est. $0.26
1 year
+62.6%
from $33.69 · Oct 27
30 days
−2.5%
from $56.19
52-week range
$26.94–59.06
−7% from high · low Mar 12
Avg volume 20D
1.55M
shares / day
Short interest
🔒 Subscribers only
Insider net
−$274.8K
0 buyers · 1 seller · 12 mo
New fund stakes
3
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 9, 2026
Strongest MIXED TG Therapeutics reported Q2 2026 total global revenue of $240.3M (up 70% YoY, beating consensus of $229.8M)…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $274.8K.

  • InstitutionsBULLISH

    Q2 2026: 47 added (3 new), 22 trimmed or exited. Largest new: Frontier Capital Management $20.3M, Point72 Asset Management, $14.6M.

  • AnalystsBULLISH

    12 of 14 rate it Buy or better. Median target $75.00 (+37%).

  • EstimatesFALLING

    Current-quarter EPS estimate $0.435 → $0.258 over 90 days. 0 up, 2 down in 30 days.

  • TrendRANGE

    0% above its 50-day average.

Who's buying

13F· Q2 2026
3
new positions
0
exits
$45.1M
in new stakes
FundMoveSharesValue
D. E. Shaw & Co., Inc.DOUBLED3,400,808$186.8M
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED2,767,656$152.1M
FMR LLCDOUBLED1,018,814$56.0M
BARCLAYS PLCDOUBLED957,848$52.6M
VOYA INVESTMENT MANAGEMENT LLCADD819,253$45.0M
RENAISSANCE TECHNOLOGIES LLCADD679,300$37.3M
HRT FINANCIAL LPDOUBLED622,603$34.2M
RAYMOND JAMES FINANCIAL INCADD620,280$34.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 86% rate it Buy or better
Strong Buy3Buy9Hold1Sell1Strong Sell0
12-month targets · 7 analysts

Price is inside the target range. Median implies +37%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 1, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 7, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Jul 27, 2026B. Riley Securities
MAINTAIN
MAINTAINBuy
Jul 13, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 7, 2026B of A Securities
MAINTAIN
MAINTAINUnderperform
Jul 6, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$274.8K
sold · 1 insider
DateInsiderTypeValue
Sep 10, 2026
Charney Laurence N
Director
SELL$274.8K
Aug 7, 2026
Charney Laurence N
Director
GIFT500 sh
Aug 7, 2026
Charney Laurence N
Director
GIFT450 sh
Aug 6, 2026
Charney Laurence N
Director
GIFT5,100 sh
Jun 11, 2026
Charney Laurence N
Director
AWARD8,325 sh
Jun 11, 2026
Echelard Yann
Director
AWARD8,325 sh
Jun 11, 2026
Hoberman Kenneth
Director
AWARD8,325 sh
Jun 11, 2026
Lonial Sagar
Director
AWARD8,325 sh

Earnings setup

Estimates
Nov 9
reports in 13 days
$0.26
EPS estimate, this quarter
−41%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.26$0.19–$0.35-21.5%$245.4M
Next Q$0.41$0.33–$0.45-8.6%$269.5M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 Other
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inve
Sep 10, 2026 Insider
Charney Laurence N sold 5,000 shares
Director @ $54.96 ($274.8K)
Aug 7, 2026 Insider
Charney Laurence N gifted 500 shares
Director
Aug 7, 2026 Insider
Charney Laurence N gifted 450 shares
Director
Aug 3, 2026 SEC
TG Therapeutics reported Q2 2026 total global revenue of $240.3M (up 70% YoY, beating consensus of $229.8M) and raised…
8-K — Impact 6/10
Jun 30, 2026 Inst.
D. E. Shaw & — DOUBLED
3,400,808 shares ($186.8M)
Jun 30, 2026 Inst.
PRICE T ROWE ASSOCIATES — DOUBLED
2,767,656 shares ($152.1M)
Jun 11, 2026 SEC
In Q3 2024, institutional activity in TGTX reveals a sharp split: 16 buyers added $41.8M in positions, led by asset…
INST-CLUSTER — Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
TGTX Q3 2026 Earnings Scheduled — 2026-11-09
Recent
Sep 28, 2026
Press release
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors…
Sep 10, 2026
Press release
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET
Sep 3, 2026
Press release
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
Fireside chat scheduled for Wednesday, September 9, 2026, at 11:30am ET Fireside chat scheduled for Wednesday, September 9, 2026, at 11:30am ET
Aug 3, 2026
Earnings
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million
Aug 3, 2026
Earnings date
TGTX Q2 2026 Earnings Scheduled — 2026-08-03

SecBot reports

7 filings · 6 press releases · 4 bullish · 0 bearish · 2 mixed · 1 neutral
All TGTX filing & press-release reports (13)